Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Jun Gong MD

Jun Gong MD

Assistant Professor, Department of Medicine, Division of Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, California

Jun Gong, MD, is an Assistant Professor in the Department of Medicine, Division of Hematology and Oncology at Cedars-Sinai Medical Center. As a medical oncologist, his primary clinical interests are in gastrointestinal (GI), hepatobiliary, and genitourinary (GU) cancers with a multidisciplinary focus of care along with colleagues from surgery, gastroenterology, radiation oncology, radiology, and urology. Dr. Gong is focused on translational and clinical cancer research with interests in early therapeutic trials (immunotherapy, targeted therapies, biologics, and other systemic therapies) and biomarker development to improve patient outcomes in GI and GU cancers. 

Disclosures

Consultant or Advisory Role – EMD Serono, Elsevier, Exelixis, QED Therapeutics, Natera, Basilea, HalioDx, Eisai, Janssen, Astellas, Amgen, Pfizer, Seagen, and Bayer.

Recent Contributions to PracticeUpdate:

  1. A New Strategy for the Treatment of Sorafenib-Refractory mRCC in China
  2. The VENUSS Prognostic Model Predicts Disease Recurrence Following Surgery for Non-Metastatic Papillary RCC
  3. Prognostic Factors for Survival After Curative Nephrectomy in Nonmetastatic RCC
  4. Effect of Antibiotic Use on Outcomes With Systemic Therapies in Metastatic Renal Cell Carcinoma
  5. Renal Mass Biopsy Is Associated With Surgery Reduction for Early-Stage Kidney Cancer
  6. The Prognostic Effect of the Immunoscore in Patients With ccRCC
  7. Pathologic Response and Surgical Outcomes in Patients Undergoing Nephrectomy Following Receipt of Immune Checkpoint Inhibitors for RCC
  8. ESMO 2019: Recommendations From Dr. Jun Gong
  9. Patient Factors in the Real World Selection of First-Line mRCC Treatment: An Update From ESMO 2016

Elsewhere

Recently Updated